Neurofibromatosis Type 2 (NF2) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032
Neurofibromatosis type 2 (NF2) is an
autosomal-dominant tumor-prone disorder predisposed to nerve system tumors.
Bilateral vestibular schwannoma (VS) is pathognomonic or the disease, whereas
schwannoma at other locations, meningiomas, ependymomas, and early onset
lenticular opacities are frequently associated with the phenotypes. Vestibular
schwannoma-related symptoms were seen in most of the patients (55%), followed
by ophthalmological symptoms/abnormalities (45%) and cutaneous features (38%).
About 40% of all patients were monosymptomatic, 55% showed ≥2 symptoms at
symptom onset, and ~5% were asymptomatic. Including polysymptomatic occurrence
and symptomatic and asymptomatic findings, 62% of young patients exhibit
ophthalmological abnormalities, followed by cutaneous findings (43%). Most
people with NF2 develop symptoms in the late teen and early adult years,
although about 10% of people develop symptoms during late childhood. The most
common symptoms of NF2 include ringing in the ears (tinnitus), gradual hearing
loss, and balance problems.
Neurofibromatosis type 2 (NF2) incidence
ranges from 1 to 1.2 cases in 40,000 live birth Neurofibromatosis type 2 (NF2).
The competitive
landscape of Neurofibromatosis Type 2 (NF2) includes country-specific approved
and pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Neurofibromatosis
Type 2 (NF2) across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Neurofibromatosis
Type 2 (NF2) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 REC-2282 Recursion
Pharmaceuticals Inc. Phase 3
2 Icotinib Betta
Pharmaceuticals Co., Ltd. Phase 2
3 VT3989 Vivace
Therapeutics, Inc Phase 1
4 IK-930 Ikena Oncology Phase 1
5 Mirdametinib (PD-0325901) SpringWorks
Therapeutics, Inc. Phase 2
6 Endostatin Shandong
Simcere-Medgenn Bio-pharmaceutical Co., Ltd Phase 2
Comments
Post a Comment